Results 61 to 70 of about 19,263 (243)

Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma

Blood Science, 2022
Plasmablastic lymphoma (PBL) is an aggressive lymphoma with limited treatment strategies. Tuberculosis (TB) infection poses a high risk for patients with hematologic malignancies, especially those treated with immune agents but were never reported post ...
Wenyue Cao, Yuling Wan, Xingcheng Yang, Wei Huang, Jia Wei   +4 more
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine

International Journal of Infectious Diseases
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment.
Simon B. Gressens, Vincent Enouf, Antoine Créon, Giovanna Melica, Francois Lemonnier, Jehan Dupuis, Taoufik El Gnaoui, Mohammad Hammoud, Karim Belhadj, Corinne Haioun, Anne Le Bouter, Sebastien Gallien, Fabien Le Bras, Slim Fourati   +13 more
doaj   +1 more source

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma [PDF]

, 2020
Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to ...
Alegre, A, Balari, AS, Blanchard, MJ, Couturier, C, de la Rubia, J, Gaudig, M, Gonzalez, MS, Hevia, H, Insunza, A, Lleonart, JB, Mateos, MV, Milionis, I, Montero, LFC, Palomera, L, Pei, HL, Penarrubia, MJ, Potamianou, A, Rios-Tamayo, R, Rodriguez, CE, Rodriguez-Otero, P, Suarez, A   +20 more
core   +1 more source

A Refractory Leg Skin Ulcer Associated With Multiple Myeloma Successfully Treated With Plasma Exchange, Lenalidomide, and Dexamethasone

JEADV Clinical Practice, EarlyView.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder that primarily presents with CRAB symptoms (calcium elevation, renal failure, anemia, and bone abnormalities). In rare cases, MM manifests with systemic complications like skin ulcers, which present management challenges. Here, we report a 78‐year‐old Japanese man with MM and refractory
Naoko Hattori, Yutaka Kuwatsuka, Tomoka Waseda, Daisuke Ehara, Koji Ando, Hiroyuki Murota   +5 more
wiley   +1 more source

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review

Journal of Family Medicine and Primary Care, 2022
Introduction: With an increase in number of cases of relapsed or refractory multiple myeloma (RRMM), scientist have discovered various combination of medications among which one is daratumumab, Daratumumab is a mono-clonal antibody which attacks CD-38 ...
Abubakar Tauseef, Maryam Zafar, Peter Silberstein, Joseph Nahas, Thomas Frederickson, Faith Abodunrin, Anum Abbas, Wafa Arshad, Noman Lateef, Hussain Rangoonwala, Sara Albagoush, Mohsin Mirza   +11 more
doaj   +1 more source

Mieloma múltiplo: evolução e novas terapêuticas [PDF]

, 2016
Monografia realizada no âmbito da unidade de Estágio Curricular do Mestrado Integrado em Ciências Farmacêuticas, apresentada à Faculdade de Farmácia da Universidade de CoimbraO Mieloma Múltiplo é uma doença hematológica maligna caracterizada pela ...
Sancho, Inês Filipa Góis
core  

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, EarlyView.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Haematologica, 2018
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or ...
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos   +36 more
doaj   +1 more source

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

JTO Clinical and Research Reports, 2021
Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC.
Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD, Patricia Lorenzini, RN, Diana A. Alvarez Arias, PhD, Christopher Moy, MS, Natalie Hutnick, PhD, Roland Knoblauch, MD, Huaibao Feng, PhD, Colleen Kane, PhD, Leora Horn, MD, Martin Reck, MD, Santiago Ponce, MD   +12 more
doaj   +1 more source